P Stephen Patrick
Overview
Explore the profile of P Stephen Patrick including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
296
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Navarrete-Leon C, Doherty A, Strimaite M, Bear J, Olivo A, Endrizzi M, et al.
Nano Lett
. 2024 Nov;
25(3):1036-1042.
PMID: 39601295
The poor soft tissue contrast of X-ray CT necessitates contrast agent use to improve diagnosis across disease applications, yet their poor detection sensitivity requires high injected doses, which restrict use...
2.
Patrick P, Stuckey D, Zhu H, Kalber T, Iftikhar H, Southern P, et al.
Nanoscale
. 2024 Jul;
16(42):19715-19729.
PMID: 39044561
Magnetic field hyperthermia relies on the intra-tumoural delivery of magnetic nanoparticles by interstitial injection, followed by their heating on exposure to a remotely-applied alternating magnetic field (AMF). This offers a...
3.
Navarrete-Leon C, Patrick P, Doherty A, Allan H, Cipiccia S, Marathe S, et al.
J Synchrotron Radiat
. 2024 Jul;
31(Pt 5):1293-1298.
PMID: 39007822
Two-directional beam-tracking (2DBT) is a method for phase-contrast imaging and tomography that uses an intensity modulator to structure the X-ray beam into an array of independent circular beamlets that are...
4.
Flechas Becerra C, Barrios Silva L, Ahmed E, Bear J, Feng Z, Chau D, et al.
Adv Sci (Weinh)
. 2023 Dec;
11(10):e2306246.
PMID: 38145968
Protein-based biomaterial use is expanding within medicine, together with the demand to visualize their placement and behavior in vivo. However, current medical imaging techniques struggle to differentiate between protein-based implants...
5.
Paliashvili K, Popov A, Kalber T, Patrick P, Hayes A, Henley A, et al.
Adv Ther (Weinh)
. 2021 Sep;
4(2):2000179.
PMID: 34527807
Recurrence of prostate cancer after radical prostatectomy is a consequence of incomplete tumor resection. Systemic chemotherapy after surgery is associated with significant toxicity. Improved delivery methods for toxic drugs capable...
6.
Helfer B, Ponomarev V, Patrick P, Blower P, Feitel A, Fruhwirth G, et al.
Cytotherapy
. 2021 Apr;
23(9):757-773.
PMID: 33832818
Cell-based therapies have been making great advances toward clinical reality. Despite the increase in trial activity, few therapies have successfully navigated late-phase clinical trials and received market authorization. One possible...
7.
Armstrong J, Keane T, Roques A, Patrick P, Mooney C, Kuan W, et al.
Sci Transl Med
. 2020 Dec;
12(572).
PMID: 33268507
The past few decades have produced a large number of proof-of-concept studies in regenerative medicine. However, the route to clinical adoption is fraught with technical and translational obstacles that frequently...
8.
Zaw Thin M, Allan H, Bofinger R, Kostelec T, Guillaume S, Connell J, et al.
Nanoscale
. 2020 Aug;
12(31):16570-16585.
PMID: 32749427
Stem cells have been utilised as anti-cancer agents due to their ability to home to and integrate within tumours. Methods to augment stem cell homing to tumours are being investigated...
9.
Patrick P, Kolluri K, Zaw Thin M, Edwards A, Sage E, Sanderson T, et al.
Stem Cell Res Ther
. 2020 Jun;
11(1):256.
PMID: 32586403
Background: MSCTRAIL is a cell-based therapy consisting of human allogeneic umbilical cord-derived MSCs genetically modified to express the anti-cancer protein TRAIL. Though cell-based therapies are typically designed with a target...
10.
Stem cell delivery to kidney via minimally invasive ultrasound-guided renal artery injection in mice
Zaw Thin M, Ogunlade O, Comenge J, Patrick P, Stuckey D, David A, et al.
Sci Rep
. 2020 May;
10(1):7514.
PMID: 32372054
Cell-based therapies are promising treatments for various kidney diseases. However, the major hurdle in initiating therapeutic responses is the inefficiency of injection routes to deliver cells to the kidney parenchyma....